Related Experiment Videos
Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer
A Milla-Santos1, L Milla, L Rallo
1The Medical Oncology Service, Nuestra Senyora Del Piltar Hospital, Barcelona, Spain.
Purpose:
Efficacy and safety of toremifene (TOR) 60 mgs/dayly/o.r. was compared with tamoxifen (TAM) 40 mgs/dayly/o.r. in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.
Material And Methods:
The study was a prospective double-blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assesed according to WHO guidelines. Curves were constructed by means of Kaplan-Meier methodology and were compared by means of log-rank test.
Results:
From January 1996 to January 1999 a total of 217 patients were included in the study (106 in the TOR branch and 111 in the TAM arm). Both groups of patients were homogeneous regarding the main prognostic factors. A response rate of 64% (68/106) was observed in the TOR group as compared with a 52% (58/111) in the TAM group. Median times to progression and overall survival were not significantly different. A lower incidence of undesirable effects was apreciated in the TOR arm.
Conclusions:
Our data suggest that TOR is an efficient and well-tolerated agent for the therapy of postmenopausal women with hormonal positive receptors advanced breast cancer, and must be considered an alternative to TAM as first line therapy for ER+ advanced breast cancer patients and as well as an adjuvant treatment.
Related Concept Videos
Clinical Trials: Overview
Treatment Resistant Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists